Market Research Industry Reports

Tuberculosis - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Tuberculosis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H1 2018, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 7, 13, 2, 55, 35 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 4, 36 and 32 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 6
Tuberculosis - Overview 7
Tuberculosis - Therapeutics Development 8
Tuberculosis - Therapeutics Assessment 31
Tuberculosis - Companies Involved in Therapeutics Development 41
Tuberculosis - Drug Profiles 65
Tuberculosis - Dormant Projects 299
Tuberculosis - Discontinued Products 309
Tuberculosis - Product Development Milestones 310
Appendix 319

List Of Tables

List of Tables
Number of Products under Development for Tuberculosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Tuberculosis - Pipeline by Abera Bioscience AB, H1 2018
Tuberculosis - Pipeline by AGILeBiotics BV, H1 2018
Tuberculosis - Pipeline by Akshaya Bio Inc, H1 2018
Tuberculosis - Pipeline by Archivel Farma SL, H1 2018
Tuberculosis - Pipeline by AstraZeneca Plc, H1 2018
Tuberculosis - Pipeline by Aucta Pharmaceuticals LLC, H1 2018
Tuberculosis - Pipeline by BioLingus AG, H1 2018
Tuberculosis - Pipeline by Bioversys AG, H1 2018
Tuberculosis - Pipeline by Celgene Corp, H1 2018
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018
Tuberculosis - Pipeline by Consegna Pharma Inc, H1 2018
Tuberculosis - Pipeline by Crestone Inc, H1 2018
Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Tuberculosis - Pipeline by Demuris Ltd, H1 2018
Tuberculosis - Pipeline by Eisai Co Ltd, H1 2018
Tuberculosis - Pipeline by Eli Lilly and Co, H1 2018
Tuberculosis - Pipeline by EpiVax Inc, H1 2018
Tuberculosis - Pipeline by Evotec AG, H1 2018
Tuberculosis - Pipeline by FIT Biotech Oy, H1 2018
Tuberculosis - Pipeline by GangaGen Inc, H1 2018
Tuberculosis - Pipeline by GC Pharma, H1 2018
Tuberculosis - Pipeline by GlaxoSmithKline Plc, H1 2018
Tuberculosis - Pipeline by Globeimmune Inc, H1 2018
Tuberculosis - Pipeline by Hager Biosciences LLC, H1 2018
Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H1 2018
Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, H1 2018
Tuberculosis - Pipeline by Immunitor Inc, H1 2018
Tuberculosis - Pipeline by ImmunoBiology Ltd, H1 2018
Tuberculosis - Pipeline by Innovare R & D SA De CV, H1 2018
Tuberculosis - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Tuberculosis - Pipeline by Johnson & Johnson, H1 2018
Tuberculosis - Pipeline by LegoChem Biosciences Inc, H1 2018
Tuberculosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2018
Tuberculosis - Pipeline by Merck & Co Inc, H1 2018
Tuberculosis - Pipeline by Microbiotix Inc, H1 2018
Tuberculosis - Pipeline by Novartis AG, H1 2018
Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2018
Tuberculosis - Pipeline by Otsuka Holdings Co Ltd, H1 2018
Tuberculosis - Pipeline by Pfizer Inc, H1 2018
Tuberculosis - Pipeline by QureTech Bio AB, H1 2018
Tuberculosis - Pipeline by Qurient Co Ltd, H1 2018
Tuberculosis - Pipeline by Recce Ltd, H1 2018
Tuberculosis - Pipeline by Rodos BioTarget GmbH, H1 2018
Tuberculosis - Pipeline by Sanofi, H1 2018
Tuberculosis - Pipeline by Sanofi Pasteur SA, H1 2018
Tuberculosis - Pipeline by Sequella Inc, H1 2018
Tuberculosis - Pipeline by Shionogi & Co Ltd, H1 2018
Tuberculosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Tuberculosis - Pipeline by Target Medicals LLC, H1 2018
Tuberculosis - Pipeline by Theravectys SA, H1 2018
Tuberculosis - Pipeline by TVAX Biomedical Inc, H1 2018
Tuberculosis - Pipeline by Vaccibody AS, H1 2018
Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2018
Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2018
Tuberculosis - Pipeline by Vaxine Pty Ltd, H1 2018
Tuberculosis - Pipeline by Vichem Chemie Research Ltd, H1 2018
Tuberculosis - Dormant Projects, H1 2018
Tuberculosis - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Tuberculosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

2018 Global Tuberculosis Diagnostic Testing Market: US, Europe, Japan--Supplier Shares, Volume and Sales Segment Forecasts, Competitive Analysis, Emerging Technologies, Instrumentation Review, Opportunities for Suppliers

The report presents a detailed analysis of the Tuberculosis diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Tuberculosis definition, epidemiology

USD 3850View Report

Global Tuberculosis (TB) Drugs/Therapeutics Market Research Report 2018

Tuberculosis (TB) Drugs/Therapeutics Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on

USD 2850View Report

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018Caspase 9 (Apoptotic

USD 3500View Report

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2018

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : May 2018
No. of Pages :339
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube